Related Experiment Video

Updated: Dec 7, 2025

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.7K

Efficacy and Cardiovascular Safety of SGLT2 Inhibitors

Cornelius James Fernandez1, Abisha Graciano Nevins2, Shasta Nawaz3

  • 1Department of Endocrinology and Metabolism, Pilgrim Hospital, Boston, PE21 9QS, United Kingdom.

Current Drug Safety
|October 2, 2020
PubMed

Insights

Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer cardiovascular and renal protection for diabetic patients, addressing a critical unmet need. These agents also promote weight reduction, aligning with ideal diabetes management goals.

Area of Science:

  • Endocrinology
  • Cardiology
  • Nephrology

Background:

  • Diabetic patients face persistent cardiovascular and renal risks despite controlled glycemic, blood pressure, and lipid levels.
  • Heart failure (HF) is a significant cause of morbidity and mortality in diabetes, often overlooked in medication studies.
  • An unmet need exists for diabetes drugs providing cardiovascular (including HF) and renal protection, alongside weight reduction.

Purpose of the Study:

  • To critically analyze the efficacy and cardiovascular safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors.
  • To guide clinical decision-making regarding the use of SGLT2 inhibitors in diabetic patients.

Main Methods:

  • Review of recently published outcome trials and international guidelines.
  • Critical analysis of available literature on SGLT2 inhibitors' efficacy and cardiovascular safety.

Main Results:

  • SGLT2 inhibitors have demonstrated reductions in cardiovascular and renal events in diabetic patients.
  • These agents are associated with statistically significant weight reduction.
  • International guidelines now recommend SGLT2 inhibitors for diabetic patients with pre-existing cardiovascular disease (CVD).

Conclusions:

  • SGLT2 inhibitors represent a significant advancement in managing cardiovascular and renal risks in diabetes.
  • Their benefits extend to HF prevention and management, addressing a key clinical gap.
  • The findings support the integration of SGLT2 inhibitors into clinical practice for comprehensive diabetes care.

Keywords:
SGLT2 Inhibitorscardiovascular benefitscardiovascular safetydiabetes mellitusefficacyrenal benefits

More Related Videos

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

485
Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane08:05

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane

Published on: December 9, 2022

4.8K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
425
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
498
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
433
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
26.9K
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
605
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
466